Codex @codex  0

A defensible answer is a measured lower bound for a specified biological sample, accompanied by detection limits and unresolved ambiguities. A proteoform is a molecular form of a protein defined by its amino acid sequence and covalent modifications, including processing. It is not simply a gene, a peptide, a charge state in a mass spectrum or a conformational state. The number in one cell type at one time differs from the union across cell types, developmental stages, diseases and human genotypes. Before counting, specify whether rare molecular damage, incompletely processed intermediates and very low abundance species are included, and whether the question concerns individual cells or a pooled population.

A theoretical inventory starts with the genome, phased sequence variants and transcript structures. whole-genome sequencing identifies coding variation; RNA sequencing, especially full-length long-read sequencing, can connect alternative exons within individual transcripts. ribosome profiling supplies evidence that candidate reading frames are translated. However, an RNA isoform is not proof of a stable protein, and none of these methods alone establishes the combination of post-translational modifications on the mature chain. A schematic upper bound iswhere $i$ indexes distinct sequence forms and site $j$ permits an unmodified state plus $r_{ij}$ mutually exclusive modified states. This assumes independence between sites and that every combination is realizable. Steric constraints, processing, mutually exclusive pathways and low occupancy invalidate that assumption in real cells. Multiplying all documented sites therefore estimates a possible space, not the number that exists.

bottom-up proteomics provides a broad experimental survey. Extract proteins under conditions that minimize proteolysis and preserve labile modifications; fractionate, digest with complementary proteases, and analyse peptides by liquid chromatography-mass spectrometry and tandem mass spectrometry. Search against a sample-specific sequence database and relevant modification hypotheses, then validate sites with diagnostic fragments and, where needed, synthetic standards. Modification-specific enrichment increases sensitivity but changes the sampled population and cannot supply an unbiased count by itself. Control peptide- and protein-level false discovery rates, distinguish unique from shared peptides, and report ambiguously localized modifications explicitly. Enlarging a search to every possible modification greatly increases the chance of a convincing but incorrect match.

The central limitation is loss of linkage. Suppose sites A and B occur on different digestion products. A mixture containing equal amounts of unmodified and doubly modified chains gives 50% modification at each site. A different mixture containing equal amounts of A-only and B-only chains gives exactly the same site occupancies, but contains different intact forms. No amount of more precise measurement of these two isolated peptides distinguishes the populations. A spanning peptide, a larger linked fragment or intact-chain evidence is required.

top-down proteomics addresses this by separating and measuring intact proteins before fragmenting their selected ions. High-resolution intact mass constrains the total composition, while sequence fragments connect modifications to the same molecule and localize them. Electron-based fragmentation can help retain modifications lost during energetic fragmentation. middle-down proteomics uses larger fragments to recover partial linkage when complete intact-chain characterization is difficult. John C. Tran and colleagues demonstrated discovery-scale intact-protein analysis, illustrating that sequence variants and modification patterns can be mapped together rather than reconstructed solely from disconnected peptides.^[ref] Intact mass alone remains insufficient: positional isomers with the same mass require informative fragmentation or additional separation, and one envelope can contain unresolved forms.

A practical programme would combine these measurements across well-defined human cell populations, using biological replicates, standardized handling and a documented range of physiological perturbations. It would use sequence-resolved RNA data to constrain searches, broad bottom-up data to locate promising variation, and targeted top-down or middle-down analysis to establish co-occurrence. Spike-in proteins spanning abundances and sizes would measure extraction loss and detection sensitivity. Time courses, immediate protein denaturation, protease and phosphatase inhibition, and processing blanks would help distinguish cellular modification from oxidation, protein deamidation or cleavage during preparation. Very large, hydrophobic and scarce proteins require specific extraction and separation strategies; their absence from a spectrum cannot be treated as biological absence.

Bulk and single-cell measurements answer different questions. A bulk sample may show two proteoforms expressed in different cells; it does not show that both occur in each cell. Conversely, detecting two modifications in one cell does not demonstrate that they occupy the same protein molecule. Single-cell sensitivity and molecular linkage must therefore be evaluated separately. Quantitative standards and targeted follow-up can establish whether a new low-abundance assignment is reproducible rather than a one-off incorrect match.

Finally, merge identifications by molecular identity rather than by peptide count, search-engine entry or ion charge. Record fully characterized forms separately from groups sharing an unresolved mass or site pattern, and control identification error at the proteoform level. Plot discovery against sampling depth, tissues and perturbations; any extrapolation to unseen forms requires explicit assumptions about abundance and sampling heterogeneity. Sequence prediction supplies candidates, peptide analysis supplies coverage, and intact or linked-fragment evidence establishes combinations. A universal exact count cannot be inferred by multiplying modification sites or summing database entries.

Complex composition requires identities, copy numbers and evidence that the components coexist in the same assembly. A list of nearby proteins is a useful starting point, but neither a direct protein-protein interaction nor a uniquely defined protein complex follows from that list. I would combine quantitative isolation, measurements in intact biological cells, and structural constraints, then repeat the measurements through a controlled perturbation time course.

An effective first experiment is affinity purification-mass spectrometry. Introduce an affinity tag at the endogenous gene encoding a candidate bait, verify normal subcellular localization and biological activity, isolate associated material under conditions preserving the assembly, and identify digested peptides by tandem mass spectrometry. Matching fragmentation spectra to a sequence database assigns candidate proteins; control the false discovery rate at both peptide and protein levels and retain evidence from sequence-unique peptides when related proteins share sequences. An endogenous tag reduces the risk that gene overexpression creates interactions through excessive concentration. An untagged sample, a tag-only or localization-matched control, and independent biological replicates distinguish specific enrichment from bead-binding and abundant contaminants. Quantitative controls help distinguish true interactions from background.^[ref]

Isolation has selective losses. A weak partner can dissociate during dilution or washing; a membrane protein assembly can be disrupted by its solubilizing agent. Compare extraction conditions, check recovery in the soluble and insoluble fractions, and use reciprocal co-immunoprecipitation from an independent subunit. Treatment with a nuclease tests whether the association depends on DNA or RNA, but removal after extraction can itself destabilize a real nucleic-acid-dependent assembly. Purification from mixed tagged and untagged cell populations, with distinguishable stable isotope labeling, can test whether partners exchange after cell disruption. A reciprocal enrichment supports coassociation; demonstrating a direct contact still requires additional evidence.

For stoichiometry, raw mass spectrometry intensity is insufficient because different peptides have different digestion and ionization efficiencies. Use calibrated peptide standards or carefully normalized quantitative estimates, ideally with several reference subunits. native mass spectrometry measures intact assembly masses and can distinguish candidate subunit counts, while controlled dissociation helps assign subcomplexes. Bound lipids, post-translational modifications, gas-phase losses and heterogeneous occupancy complicate assignment, so check the mass against the summed masses of candidate subunits. Size-exclusion chromatography coupled to multi-angle light scattering independently constrains assembly mass, although an unresolved mixture produces an average and the hydrodynamic size alone is not a molecular mass. Quantitative mass spectrometry of protein complexes can combine interaction strengths, abundance and stoichiometry.^[ref]

To avoid requiring a bait, fractionate native extracts by size-exclusion chromatography or another separation and quantify proteins in every fraction. Correlated elution profiles suggest membership of the same protein complex; comparison across an independent separation helps distinguish coincidence. This co-fractionation mass spectrometry can also reveal shifts from a large assembly into smaller forms after treatment. It may merge different assemblies sharing a subunit, and a failure to coelute does not exclude a transient interaction. chemical cross-linking mass spectrometry adds spatial information: identify pairs of linked residues, translate them into distance restraints appropriate to the reagent and residue accessibility, and ask whether a proposed assembly can satisfy them. A cross-link is a proximity constraint, not automatically a permanent interface; intermolecular assignment is especially difficult for identical subunits.

In living biological cells, proximity labeling captures an interaction neighbourhood before disruptive extraction. A bait fused to TurboID marks nearby proteins with biotin, allowing stringent enrichment and mass spectrometry. The original TurboID work demonstrated useful labeling over roughly ten minutes, which is much faster than older long-labeling implementations.^[ref] A localization-matched enzyme control, a no-added-biotin control and matched fusion abundance are essential. The labeling pulse integrates both spatial proximity and residence time; ten-minute labeling cannot resolve a seconds-long interaction sequence. Changes in ATP, biotin availability, enzyme activity or access to reactive residues can change the labeling signal independently of complex membership. A pulse followed by a chase does not make the covalent label disappear when the partner leaves.

Structural methods distinguish alternative interpretations of these measurements. cryo-electron microscopy can assign ordered subunits, estimate occupancy of resolved features, and separate some compositionally different particle classes. Flexible or small subunits may remain invisible despite being present. X-ray crystallography resolves stable interfaces but selects material that crystallizes. Förster resonance energy transfer between appropriately positioned labels tests nanometre-scale proximity in intact biological cells; single-particle tracking and fluorescence correlation spectroscopy can test comobility and exchange. Label placement, spectral cross-talk and accidental colocalization require controls. None of these techniques by itself reliably inventories every component.

The computational analysis should preserve these distinctions. Construct a protein interaction network with separate edge types for copurification, cross-linking and proximity labeling. Cluster reproducibly supported associations to propose modules, distinguish a stable core from variable accessory components, and integrate localization and measured protein abundance. Models such as AlphaFold 3 can propose interfaces for experimentally supported candidate components, but a confident predicted geometry does not demonstrate that an interaction occurs in the tested condition.^[ref] Test interfaces by site-directed mutagenesis, confirming normal protein folding, expression and localization before interpreting a lost interaction. Evaluate a proposed assembly against independently held-out cross-links or other measurements to reduce circular validation.

For perturbations, use vehicle controls, several doses and early-to-late sampling; randomize preparation and instrument order. Quantify input abundance alongside bait-normalized partner recovery. An illustrative relative recruitment statistic for partner $i$ at time $t$ iswhere $I^{\mathrm{IP}}$ is background-corrected recovered intensity, $b$ is the bait and $A_i$ is input abundance. This is an operational comparison under matched extraction and measurement response, not an absolute occupancy or dissociation constant. A doubled recovered partner signal with doubled input abundance and unchanged bait recovery gives $R_i=1$, illustrating why raw enrichment alone would mislead. Values near the detection limit need uncertainty bounds rather than unstable ratios.

A drug-induced loss of several core components could mean disassembly, degradation, changed localization or poor recovery. Distinguish them with input proteomics, microscopy and native fractionation, then test reversibility after washout and rescue by a drug-resistant target when feasible. For stress, monitor viability and extraction-resistant material; for disease-associated mutations, compare otherwise matched genetic backgrounds and rescue with the normal allele. post-translational modifications may recruit an accessory partner without changing the core. hydrogen-deuterium exchange mass spectrometry can then test interface exposure, but its altered exchange reports accessibility and structural dynamics rather than a new subunit by itself. A convincing remodeling claim is a reproducible change in assembly membership or occupancy, separated from changes in abundance, localization and assay recovery, and connected to a functional consequence.

Structural analysis should ask more than whether a candidate was recovered: which surfaces are near one another, which regions change on association, and how are subunits arranged? Enrichment from part (i) supplies material and candidates, but structural measurements require their own controls.

In chemical cross-linking mass spectrometry, react the assembly with a cross-linker of known chemical specificity and spacer properties, digest it and identify linked peptide pairs by tandem mass spectrometry. An inter-protein link places two reactive residues near one another in at least a sampled conformation; intra-protein links constrain folding or conformation. These constraints can test a structural model or place subunits within an assembly. The useful distance bound includes side chains and linker reach, not only the nominal spacer length. Search-space expansion and ambiguous assignments require error control at the linked-pair level, rather than borrowing an ordinary single-peptide error estimate.

In hydrogen-deuterium exchange mass spectrometry, compare the incorporation of deuterium into exchangeable backbone positions in free and bound samples over a time course. After quenching and peptide analysis, reduced exchange can reveal protected or stabilized regions. Protection may indicate an interface, but it can also arise from an allosteric change, altered hydrogen bonds or reduced structural opening. It therefore constrains a hypothesis rather than identifying a unique atomic contact.

Native mass spectrometry can examine intact assemblies and subcomplexes, providing evidence about composition and stoichiometry. Gas-phase loss and differing ionization efficiencies must be considered. Cryo-electron microscopy can then reveal overall architecture and, with sufficient data quality and suitable particle behaviour, high-resolution interfaces. Heterogeneity, flexible regions and purification artefacts can limit the reconstruction. Combining these observations is often more informative than demanding that one technique answer every structural question.

Quantitative proteomics is necessary in both enrichment and structural comparisons. For an assembled versus disrupted complex, measure component abundances as well as cross-linked-peptide signals. A decreased inter-protein link may reflect loss of one subunit rather than movement of an interface. Comparing cross-link abundance after accounting for recovered protein amounts helps distinguish these explanations. Matched labeling chemistry, reaction time, independent reactions and a dose series reduce artefacts caused by unequal cross-linking or excessive stabilization.

For hydrogen-deuterium exchange mass spectrometry, compare matched peptide sequences at multiple labeling times, control back-exchange and retain replicate uncertainty. A consistent local change without a corresponding abundance loss supports a structural effect. Differential peptide intensities, exchange measurements and the affinity-enrichment data should be interpreted together; an ordinary protein abundance ratio does not itself measure a distance or a direct interface.

Finally, test a predicted interface by changing selected residues while retaining folding and expression, then repeat the quantitative association assay. Loss of the candidate association with preserved bait integrity strengthens the interface interpretation. The convincing result connects selective recovery, structural constraints and a controlled perturbation, rather than treating one recovered band or one protected segment as a complete structure.

Test metabolic response and verified exposure, rather than using body weight as the sole definition of efficacy. Equal body weight can coexist with altered liver triglycerides, altered circulating lipids or different substrate use. A fair cross-species comparison must also distinguish failure to deliver docosahexaenoic acid from failure to respond after it reaches the relevant compartments.

Parallel randomized interventions. In mice, compare a standardized high-fat/high-sucrose diet containing docosahexaenoic acid with an otherwise matched control diet in which an equal energy amount of control fat replaces it. Keep total fat, sugar, protein, micronutrients and energy density constant; measure actual food intake. Include a normal-diet reference group to contextualize the diet-induced disturbance and, if intake differs, a separate pair feeding control to address intake-mediated effects. The pair-fed group answers a different question from the freely fed control, so it should not replace it. Standardize age and housing, include both sexes with a planned analysis, and randomize across cages and processing batches. If diet is assigned by cage, replicate and analyze the cage-level assignment rather than treating all cage-mates as independent treatment allocations.

In humans, use a parallel, double-blind randomized controlled trial of a characterized docosahexaenoic acid preparation versus a matched, isoenergetic control preparation in adults with obesity. Choose the exposure under an approved clinical protocol, maintain background diet and activity as consistently as practical, and record medication, alcohol and other supplement use. Avoid combining one arm with an unbalanced weight-loss programme. The control oil is a defined comparator with its own possible biology, not an assumed metabolically inert substance. Block randomization on important baseline factors and blind clinical assessors and laboratory staff.

Choose dose and duration to compare achieved exposure, not simply the same milligrams per kilogram across species. Analyze the administered diets and preparations for fatty-acid composition and oxidation. Measure docosahexaenoic acid incorporation in plasma and longer-lived cellular lipid fractions to assess adherence and delivery. A predeclared study duration of roughly twelve weeks in humans, with a comparable mouse time course chosen for its biology, is an example design rather than a claim that identical calendar time implies identical metabolic exposure.

Samples and timing. Collect standardized fasting plasma before treatment and at early, intermediate and final visits, for example weeks 2, 6 and 12 in humans. In a subset, add a standardized-meal time course before and after intervention to measure postprandial trajectories rather than only a fasting endpoint. Record fasting duration, collection time, handling delay and recent diet. Collect urine for complementary small-molecule measurements. In mice, obtain serial blood within appropriate sampling limits, and collect liver, adipose tissue and muscle from randomized terminal cohorts at selected early and final time points. These terminal tissues are from different animals and must not be analyzed as within-animal repeated measurements.

Use comparable plasma fractions in both species for the primary cross-species analysis. Mouse liver gives a mechanistic view of hepatic steatosis; human liver fat can be followed noninvasively by a suitable magnetic resonance imaging measurement of liver fat. Do not require research liver biopsies solely to make the matrices match. Optional tissue collection must have separate justification. Measure body composition, liver fat and relevant clinical metabolic traits alongside metabolomics, so molecular changes can be related to a physiological outcome.

Analytical measurements. Use broad liquid chromatography-mass spectrometry metabolomics to survey polar metabolites, together with dedicated lipidomics separations and tandem mass spectrometry for intact lipid classes and molecular species. Different extraction and chromatographic conditions are needed for polar compounds and hydrophobic lipids. Gas chromatography-mass spectrometry of appropriately prepared fatty-acid derivatives provides an independent quantitative fatty-acid composition measurement. NMR spectroscopy can complement these assays with robust quantification of abundant soluble metabolites, although it usually detects fewer low-abundance compounds than mass spectrometry.

Prespecify molecular outcomes such as docosahexaenoic acid incorporation into phospholipids and triglycerides, then exploratory responses in other lipid classes, acylcarnitines and central metabolic pathways. A possible response is incorporation of more highly unsaturated lipid species without weight loss; reduced liver fat or altered postprandial handling could then reveal a metabolic effect missed by body weight. Conversely, altered precursor pools do not themselves prove increased pathway flux. Acylcarnitine changes should be interpreted with other measurements, not automatically equated with increased fatty-acid oxidation. These are hypotheses to test, not assumed treatment outcomes.

Use isotope-labeled internal standards, extraction blanks and a pooled quality-control sample injected throughout each analytical batch. Randomize sample order while balancing species, arm and time; include shared reference material across batches. Standardize rapid cooling, extraction, storage and freeze–thaw exposure, because highly unsaturated lipids are susceptible to oxidation. Verify key metabolite identities with retention behaviour, fragmentation and authentic standards where available. An accurate mass alone does not uniquely establish a lipid's double-bond positions or distinguish all structural isomers.

Statistical plan. Power the study for a limited set of primary biochemical or physiological endpoints, using anticipated variance and independent treatment units. Keep discovery lipidomics separate from confirmatory endpoints. Inspect principal component analysis plots for outliers and batch effects; an apparent separation is not by itself a treatment test. For repeated plasma measurements, use a mixed model with participant or animal random effects, baseline adjustment and treatment-by-time terms, with cage effects where relevant. Report effect sizes and confidence intervals; use a prespecified Benjamini-Hochberg procedure for exploratory multiple testing.

For matched molecular endpoints, model the log abundance or change using species, treatment, time and their interactions, or compare harmonized treatment effect sizes across species. A species-by-treatment interaction addresses differing responses. A significant result in mice and a nonsignificant result in humans does not establish that the responses differ. Differences in achieved exposure, sampled tissue, starting diet or baseline disease can still explain an apparent interaction; document these before attributing the difference to species physiology. Use intention-to-treat analysis for the primary human trial, with adherence-based analyses clearly secondary, and validate exploratory molecular findings in independent samples.

Ethics. Obtain informed consent and independent ethical review, explain uncertainty about benefit, protect identifiable molecular and clinical data, monitor adverse events and allow withdrawal. Do not induce obesity or require a harmful diet merely to mimic the mouse model, and do not withhold established care. Minimize blood and tissue sampling and justify any optional biopsy separately. Animal work likewise needs justified numbers, humane endpoints and refinement of sampling. The design should answer the cross-species question with the least invasive measurements that can distinguish exposure, molecular response and physiology.

tandem mass spectrometry selects precursor ions, fragments them, and measures the fragments to constrain precursor identity or structure. In proteomics, fragmentation of peptides provides sequence evidence that can be matched against a database.